GOSS

Stock Option Grants: Gossamer Bio's Board of Directors approved stock option awards for two non-executive employees, allowing them to purchase up to 87,500 shares at an exercise price of $2.94 per share, effective September 5, 2025.

Vesting Schedule: The options will vest over four years, with 25% vesting on the one-year anniversary and the remainder in monthly installments, contingent on the employees' continued employment.

Company Focus: Gossamer Bio is a late-stage biopharmaceutical company dedicated to developing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Investor Relations Contact: For further inquiries, investors and media can contact Bryan Giraudo, Chief Operating Officer and Chief Financial Officer, via the provided email.

Analyst Upgrades: Top Wall Street analysts have upgraded several companies, including Gossamer Bio, Newmont Corporation, NIKE, and Saia, with significant increases in their price targets.

Specific Upgrades: Gossamer Bio was upgraded from Neutral to Buy with a price target raised to $9; Newmont Corporation was upgraded to Outperform with a target of $95; NIKE was upgraded to Buy with a target of $85; and Saia was upgraded to Positive with a target of $360.

NASDAQ 100 After Hours Performance: The NASDAQ 100 is up 103.43 points to 23,334.54, with a total after-hours volume of 150,825,985 shares traded, featuring several active stocks like AT&T, Alphabet, and Apple, all showing positive or stable performance.

Stock Recommendations: Most of the active stocks, including AT&T, Alphabet, NVIDIA, and Bank of America, have mean recommendations in the "buy range," indicating positive investor sentiment and potential for growth.